title: Efficacy of tacrolimus in Sjögren's syndrome-associated CNS disease with aquaporin-4 autoantibodies.
authors.forename: Taku
authors.initials: T
authors.lastname: Fukuda
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Shiraishi
authors.forename: Tatsufumi
authors.initials: T
authors.lastname: Nakamura
authors.forename: Keiko
authors.initials: K
authors.lastname: Tanaka
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Akira
authors.initials: A
authors.lastname: Tsujino
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nishiura
authors.forename: Toshiro
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Motomura
authors.forename: Katsumi
authors.initials: K
authors.lastname: Eguchi
mesh_terms: D051401:Aquaporin 4 / Q000276:immunology*; D001323:Autoantibodies / Q000378:metabolism*; D001921:Brain / Q000473:pathology; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013116:Spinal Cord / Q000473:pathology; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: C496030:AQP4 protein, human; D051401:Aquaporin 4; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D016559:Tacrolimus